Acute Effects of Neurodynamics on Strength and Endurance in Athletes

July 20, 2026 updated by: Tommy Wyatt, High Point University

Acute Effects of Neurodynamics on Strength and Endurance in Athletes: A Randomized Control Trial

This study explores the acute effects of neurodynamics, an intervention commonly used by physical therapist to improve nerve mobility and decrease pain, on the strength and muscular endurance in the athletic population. This study aims to find if these interventions can maintain or promote strength and endurance in the hamstrings. The studies results will help physical therapist better prescribe exercise and hands-on treatment for hamstring and sciatic nerve related conditions and injuries.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
45

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • North Carolina
      • High Point, North Carolina, United States, 27268
        • Recruiting
        • High Point University
        • Contact:
        • Principal Investigator:
          • Tommy Wyatt, DPT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Participants must be between 18 and 30 years of age.
  • Must be able to read, understand, and provide informed consent, in English.
  • Must be currently participating in an organized sport (e.g. collegiate, club, or competitive recreational level) or engaging in structured resistance training and athletic conditioning for recreational sports events (e.g 5k, marathon, Crossfit, Hyrox, etc).
  • Medically stable with no known contraindications to physical exertion.
  • Cleared for participation in strength or maximal-effort isometric testing.
  • Be able to perform lower extremity isometric testing without pain that limits maximal effort.
  • Must have 2 lower extremities capable to producing full range knee flexion and extension range of motion.
  • No medical condition that significantly alters lower extremity neuromuscular performance.
  • No history of lower extremity surgery in the past 12 months.

Exclusion Criteria:

  • Individuals younger than 18 or older than 30.
  • Acute lower extremity injury in the last 12 weeks.
  • Lower extremity surgery within the last 12 months.
  • Pain in either lower extremity that would limit maximal physical exertion.
  • History of neurological disorders, including but not limited to: Neuropathy, Stoke, MS, Parkinson's Disease, etc.
  • Use of medications that significantly impact neuromuscular performance, strength or fatigue.
  • No supplementation that affects neuromuscular performance, strength, or fatigue.
  • Unable to read and understand English.
  • Not in a vulnerable population: Pregnant, mentally or physically challenged, cognitively impaired.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Sliders
Manually applying slider technique of neurodynamics.
Other: Sciatic Slider
Mobility of a nerve, by placing tension on one end of the nerve and slacking (removing) tension off the other side of the nerve, through a full range of motion.
Active Comparator: Tensioners
Manually applied tensioner, neurodynamic technique
Other: Sciatic Tensioner
Loading the nerve, by placing tension on both ends of the nerve, isometrically at end range of motion.
Experimental: Mechanically Loaded Neurodynamics
Externally loaded neurodynamic intervention in the slider technique.
Other: Mechanically loaded neurodynamic sciatic floss
Placing tension on one end of the nerve while taking the tension off the other end, under external load of an elastic resistance band.
Device: Elastic Resistance Band
Elastic resistance band was used to provide submaximal resistance during the mechanically loaded neurodynamic intervention.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Isometric Strength
Time Frame: From initial strength and endurance test, to the post intervention strength and endurance test, assessed during a single study visit, assessed up to 30 minutes.
Isometric strength of the hamstrings in knee flexion.
From initial strength and endurance test, to the post intervention strength and endurance test, assessed during a single study visit, assessed up to 30 minutes.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Endurance Ratio (isokinetic)
Time Frame: From initial endurance test to post intervention endurance test, during a single study visit, assessed up to 30 minutes.
Endurance ratio of knee flexion, measured isokinetically.
From initial endurance test to post intervention endurance test, during a single study visit, assessed up to 30 minutes.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
High Point University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Tommy Wyatt, DPT, High PointUniversity

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 16, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 20, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 22, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IRB-FY2026-110

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The raw pre and post isometric and isokinetic endurance ratio data for each participant will be shared. Along with the intervention leg, testing order, intervention provided, level of athletic participation, primary sport activity, age, sex.

IPD Sharing Time Frame

From study end date, for 3 years following.

IPD Sharing Access Criteria

Yes, individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices), will be shared. Information will be available to researchers who provide a methodologically sound proposal to achieve aims in the approved proposal. Data will be available beginning 3 months and ending 36 months following article publication. Supporting documents including the study protocol and statistical analysis plan will also be available. Requests should be directed to twyatt2@highpoint.edu

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings